5-6-epoxycholesterol and Polycystic-Ovary-Syndrome

5-6-epoxycholesterol has been researched along with Polycystic-Ovary-Syndrome* in 1 studies

Trials

1 trial(s) available for 5-6-epoxycholesterol and Polycystic-Ovary-Syndrome

ArticleYear
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:3

    Atorvastatin is known to both inhibit and induce the cytochrome P450 3A4 (CYP3A4) enzyme in vitro. Some clinical studies indicate that atorvastatin inhibits CYP3A4 but there are no well-controlled longer term studies that could evaluate the inducing effect of atorvastatin. We aimed to determine if atorvastatin induces or inhibits CYP3A4 activity as measured by the 4β-hydroxycholesterol to cholesterol ratio (4βHC : C).. In this randomized, double-blind, placebo-controlled 6 month study we evaluated the effects of atorvastatin 20 mg day(-1) (n = 15) and placebo (n = 14) on oxysterol concentrations and determined if atorvastatin induces or inhibits CYP3A4 activity as assessed by the 4βHC : C index. The respective 25-hydroxycholesterol and 5α,6α-epoxycholesterol ratios were used as negative controls.. Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. The mean 4βHC : C ratio decreased by 13% (0.214 ± 0.04 to 0.182 ± 0.04, P = 0.024, 95% confidence interval (CI) of the difference -0.0595, -0.00483) in the atorvastatin group while no significant change occurred in the placebo group. The difference in change of 4βHC : C between study arms was statistically significant (atorvastatin -0.032, placebo 0.0055, P = 0.020, 95% CI of the difference -0.069, -0.0067). The ratios of 25-hydroxycholesterol and 5α,6α-epoxycholesterol to cholesterol did not change.. The results establish atorvastatin as an inhibitor of CYP3A4 activity. Furthermore, 4βHC : C is a useful index of CYP3A4 activity, including the conditions with altered cholesterol concentrations.

    Topics: Adult; Atorvastatin; Cholesterol; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Female; Humans; Hydroxycholesterols; Middle Aged; Polycystic Ovary Syndrome

2015